Ning Li
China Academy of Chinese Medicine Science, China
Title: Study on Peptide-based High Density Lipoprotein (pHDL) Targeting Atherosclerosis
Biography
Biography: Ning Li
Abstract
Atherosclerosis (AS) is a leading cause of death and loss of productive life worldwide. The immature form of High-density lipoprotein (HDL) has been shown advantageous in improving plaque targeting and antiAS efficacy. However, the prohibitive cost of ApoA-I protein used to generate functional HDL and the time-consuming procedure of HDL synthesis impeded its clinical application. Though HDL mimic peptides are capable of fulfilling HDL function with a dramatic low-cost, their instability in vivo failed to put their utilization into practice. Our current study was designed to synthesize peptide-based HDL (pHDL) in order to increase in vivo stability of peptides by incorporating with phospholipids. PHDL produced by microfluidics resulted in discoidal nano-scale particles, showing of 37.8 nm diameter, 0.275 PdI and -4.17 mV zeta potential. Using in vivo imaging system, FITC-labeled pHDL was highly recruited to the aorta of AS model ApoE-/- mice compared to C57BL/6 control mice，24 hrs post-intraperitoneal injection. Intraperitoneal administration of pHDL to ApoE-/- mice twice per week for 12 weeks reduced more than 40% plasma TG, TC and LDL-C, which leads to 40% reduction of aortic plaques. In addition, increase of plasma ALT, AST and creatinine in ApoE-/- mice were largely improved by pHDL treatment, indicating a general protective effect of pHDL. In conclusion, pHDL represents an affordable alternative of HDL, in terms of plaque-targeting and anti-AS effects.